Octapharma Sustainability Profile
Octapharma AG, headquartered in Switzerland (CH), is a leading global player in the biopharmaceutical industry, specialising in the development and production of human proteins derived from human plasma and recombinant technologies. Founded in 1983, Octapharma has established a strong presence in Europe, North America, and Asia, with a commitment to innovation and quality. The company’s core product offerings include a range of immunoglobulins, coagulation factors, and albumin, which are essential for treating various medical conditions, including immune deficiencies and bleeding disorders. Octapharma is renowned for its dedication to patient safety and product efficacy, setting it apart in a competitive market. With a robust pipeline and a focus on research and development, Octapharma has achieved significant milestones, positioning itself as a trusted name in the biopharmaceutical sector, committed to improving patient outcomes worldwide.
DitchCarbon Score
How does Octapharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Octapharma's score of 39 is higher than 58% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Octapharma's reported carbon emissions
In 2024, Octapharma reported total carbon emissions of approximately 26187000 kg CO2e for Scope 1, 29928000 kg CO2e for Scope 2, and significant contributions from Scope 3 emissions, including 93525000 kg CO2e from capital goods and 101007000 kg CO2e from purchased goods and services. This reflects a comprehensive approach to emissions reporting, covering all three scopes. The company has made notable strides in its climate commitments, achieving a 22% reduction in overall emissions since 2019, with a target of reaching a 30% reduction by 2028. Furthermore, Octapharma is committed to achieving Net Zero emissions by 2050, demonstrating a long-term vision for sustainability. In the UK, Octapharma's emissions for 2023 were reported at 177000 kg CO2e, with Scope 1 emissions at 102000 kg CO2e, Scope 2 at 4000 kg CO2e, and Scope 3 at 71000 kg CO2e. This data underscores the company's ongoing efforts to monitor and reduce its carbon footprint. Overall, Octapharma's emissions data and climate commitments reflect a proactive stance in addressing climate change, aligning with industry standards and expectations for corporate responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2024 | |
|---|---|
| Scope 1 | 26,187,000 |
| Scope 2 | 29,928,000 |
| Scope 3 | 303,021,000 |
How Carbon Intensive is Octapharma's Industry?
How Carbon Intensive is Octapharma's Location?
Octapharma's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 33% of Scope 3 emissions.
Top Scope 3 Categories
Octapharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Octapharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
